Pegargiminase - Polaris Pharmaceuticals
Alternative Names: ADI-PEG; ADI-PEG 20; ADI-SS PEG; Arginine deiminase pegylated; Arginine deiminase-PEG; Hepacid; Melanocid; PEG arginine deiminase; Pegylated arginine deiminase - Polaris GroupLatest Information Update: 28 Jun 2024
At a glance
- Originator Phoenix Pharmacologics
- Developer Barts and The London School of Medicine and Dentistry; Memorial Sloan-Kettering Cancer Center; Polaris Pharmaceuticals; University of Miami; Washington University School of Medicine
- Class Antineoplastics; Hepatoprotectants; Hydrolases; Polyethylene glycols; Proteins; Radiosensitisers
- Mechanism of Action Arginine deiminase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preregistration Malignant-mesothelioma
- Phase III Leiomyosarcoma; Liver cancer; Soft tissue sarcoma
- Phase II/III Glioblastoma
- Phase II Acute myeloid leukaemia; Malignant melanoma; Non-alcoholic steatohepatitis; Non-Hodgkin's lymphoma; Small cell lung cancer
- No development reported Bladder cancer; Breast cancer; Cancer; Gastrointestinal cancer; Head and neck cancer; Lymphoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Uveal melanoma; Viral infections
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in Taiwan (IM)
- 09 Apr 2024 Pharmacodynamics data from a preclinical trial in Uveal melanoma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Apr 2024 Polaris Pharmaceuticals plans a clinical trial for Uveal melanoma (Combination therapy) in December 2024